BR112012024708A2 - composição de compostos orgânicos - Google Patents

composição de compostos orgânicos

Info

Publication number
BR112012024708A2
BR112012024708A2 BR112012024708A BR112012024708A BR112012024708A2 BR 112012024708 A2 BR112012024708 A2 BR 112012024708A2 BR 112012024708 A BR112012024708 A BR 112012024708A BR 112012024708 A BR112012024708 A BR 112012024708A BR 112012024708 A2 BR112012024708 A2 BR 112012024708A2
Authority
BR
Brazil
Prior art keywords
composition
organic compounds
dementia
peptide
construct
Prior art date
Application number
BR112012024708A
Other languages
English (en)
Inventor
Ana Graf
Georges Imbert
Katja Baer
Marie-Emmanuelle Riviere
Marie-Jose Hoellinger
Peter Ulrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012024708(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112012024708A2 publication Critical patent/BR112012024708A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Abstract

composição e compostos orgânicos. a presente invenção se refere a composições compreendendo um construto compreendendo o peptídeo a<225>-6 e um adjuvante farmaceuticamente aceitável, para o tratamento de pacientes que sofrem de demência, em particular, demência do tipo alzheimer.
BR112012024708A 2010-03-29 2011-03-28 composição de compostos orgânicos BR112012024708A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10158273 2010-03-29
US36169710P 2010-07-06 2010-07-06
PCT/EP2011/054735 WO2011120924A1 (en) 2010-03-29 2011-03-28 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Publications (1)

Publication Number Publication Date
BR112012024708A2 true BR112012024708A2 (pt) 2016-06-07

Family

ID=42285305

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024708A BR112012024708A2 (pt) 2010-03-29 2011-03-28 composição de compostos orgânicos

Country Status (23)

Country Link
US (4) US20130011431A1 (pt)
EP (1) EP2552489A1 (pt)
JP (2) JP6088422B2 (pt)
KR (1) KR20130018407A (pt)
CN (2) CN104436212A (pt)
AR (1) AR080810A1 (pt)
AU (1) AU2011234656B2 (pt)
BR (1) BR112012024708A2 (pt)
CA (1) CA2793580A1 (pt)
CL (1) CL2012002685A1 (pt)
CO (1) CO6630127A2 (pt)
EC (1) ECSP12012180A (pt)
GT (1) GT201200265A (pt)
IL (1) IL221540B (pt)
MA (1) MA34084B1 (pt)
MX (1) MX2012011340A (pt)
NZ (1) NZ601729A (pt)
PE (1) PE20130642A1 (pt)
RU (1) RU2603486C2 (pt)
SG (2) SG10201505374TA (pt)
TN (1) TN2012000431A1 (pt)
TW (2) TW201618806A (pt)
WO (1) WO2011120924A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
PL3137093T3 (pl) * 2014-04-29 2018-06-29 Affiris Ag Leczenie i profilaktyka choroby Alzheimera (AD)
WO2015165971A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
KR102460465B1 (ko) * 2014-04-29 2022-10-27 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방
CN106659736A (zh) * 2014-04-29 2017-05-10 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
WO1999002132A2 (en) * 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
AU2002330681C1 (en) * 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
CN101711865A (zh) * 2002-07-19 2010-05-26 希托斯生物技术股份公司 含有淀粉样β1-6抗原阵列的疫苗组合物
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
CA2580208A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CN101318015A (zh) * 2008-06-25 2008-12-10 中山大学 老年性痴呆重组蛋白疫苗及其制备方法

Also Published As

Publication number Publication date
TW201138805A (en) 2011-11-16
AR080810A1 (es) 2012-05-09
CO6630127A2 (es) 2013-03-01
JP2013523682A (ja) 2013-06-17
PE20130642A1 (es) 2013-06-19
CA2793580A1 (en) 2011-10-06
JP6088422B2 (ja) 2017-03-01
SG10201505374TA (en) 2015-08-28
MA34084B1 (fr) 2013-03-05
JP2017008035A (ja) 2017-01-12
GT201200265A (es) 2014-03-14
US20150297692A1 (en) 2015-10-22
NZ601729A (en) 2013-10-25
AU2011234656B2 (en) 2013-08-01
US20160101167A1 (en) 2016-04-14
KR20130018407A (ko) 2013-02-21
WO2011120924A1 (en) 2011-10-06
IL221540B (en) 2018-11-29
US20140348871A1 (en) 2014-11-27
AU2011234656A1 (en) 2012-10-11
ECSP12012180A (es) 2012-10-30
CL2012002685A1 (es) 2013-01-25
RU2603486C2 (ru) 2016-11-27
TW201618806A (zh) 2016-06-01
MX2012011340A (es) 2012-11-16
TN2012000431A1 (en) 2014-01-30
EP2552489A1 (en) 2013-02-06
SG183806A1 (en) 2012-10-30
CN104436212A (zh) 2015-03-25
CN102834118A (zh) 2012-12-19
RU2012145734A (ru) 2014-05-10
US20130011431A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
BR112012024708A2 (pt) composição de compostos orgânicos
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
GT201300165A (es) Compuestos y su uso como inhibidores de bace
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
BR112014001801A2 (pt) indazóis
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
MX2012000973A (es) Compuestos para la reduccion de produccion de beta- amiloide.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
CR20110255A (es) Nuevos compuestos 578
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
BR112013007362A2 (pt) composição farmacêutica
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
CR20120264A (es) Compuestos
IN2012DN03182A (pt)
NI201200168A (es) Formulaciones farmacéuticas
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MA34055B1 (fr) Chlorhydrate d&#39;agomelatine hydrate et sa preparation
WO2013040227A3 (en) Therapeutic compounds
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
BR112012013199A2 (pt) composto, composição farmacêutica, e , uso de um composto
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
IN2013DN02555A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/00 (2006.01), A61K 39/385 (2006.01), A61K

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2520 DE 25/04/2019 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements